PharmAthene names Markison to board of directors

PharmAthlene, Inc., a biodefense company that develops medical countermeasures against chemical and biological threats, recently announced the appointment of Brian A. Markison to the company's board of directors.

"It is with great pleasure that we welcome Brian to PharmAthene's board of directors," Mitchel Sayare, the chairman of the board of PharmAthene, said. "With more than 30 years of distinguished service in the pharmaceutical industry in a variety of executive leadership roles, Brian's breadth of industry knowledge and experience will be an invaluable asset to PharmAthene as we chart the next phase of our company's evolution towards commercial success."
Markison was recently appointed to the position of president and chief executive officer for Nycomed U.S. and previously served as chairman, president and chief executive officer of King Pharmaceuticals, where he successfully led the company through a $3.6 billion acquisition by Pfizer.
"I am delighted to join the board of PharmAthene, particularly at this transformative time in the company's history," Markison said. "With potential revenues beginning as soon as 2012 based upon a 50/50 profit split of worldwide sales of SIGA Technologies' innovative smallpox antiviral therapy, ST-246, PharmAthene will be among a handful of biotech companies that have made the transition to a commercial stage company. I believe that my background in business development and product acquisitions will be most constructive as we divine opportunities to monetize this opportunity and build increasing value for PharmAthene shareholders."
Markison currently serves on the board of directors at Rosetta Genomics, Ltd., and Immunomedics, Inc.

PharmAthlene's lead product development programs include SparVax, a second generation recombinant protective antigen anthrax vaccine, Valortim, a fully human monoclonal antibody to prevent and treat anthrax, and Protexia, a novel bioscavenger for the treatment and prevention of morbidity and mortality associated with chemical nerve agent exposure.